ROMERIO ALESSIO

Franco, A., Aladailleh, Z., Romerio, A., Italia, A., Lami, F., Shaik, M., et al. (2025). Towards more efficient synthetic immunomodulators: biological characterization and mechanism of action of monosaccharide-derived TLR4 agonists. RSC MEDICINAL CHEMISTRY [10.1039/D4MD00950A]. Detail

Shirey, K., Romerio, A., Shaik, M., Leake, D., Palmer, C., Skupinska, N., et al. (2025). Preclinical development of the TLR4 antagonist FP12 as a drug lead targeting the HMGB1/MD-2/TLR4 axis in lethal influenza infection. INNATE IMMUNITY, 31 [10.1177/17534259241313201]. Detail

Sainz-Mejias, M., Ma, C., Hou, Y., Jurado-Martin, I., Romerio, A., Franco, A., et al. (2025). Monosaccharide-Based Synthetic TLR4 Agonist Enhances Vaccine Efficacy against Pseudomonas aeruginosa Challenge. ACS INFECTIOUS DISEASES, 11(4), 894-904 [10.1021/acsinfecdis.4c00932]. Detail

Ami, D., Franco, A., Artusa, V., Romerio, A., Shaik, M., Italia, A., et al. (2024). Vibrational spectroscopy coupled with machine learning sheds light on the cellular effects induced by rationally designed TLR4 agonists. TALANTA, 275(1 August 2024) [10.1016/j.talanta.2024.126104]. Detail

Shaik, M., Pasco, S., Romerio, A., Pifferi, C., Sesana, S., Re, F., et al. (2024). Development of a New Vaccine Adjuvant System Based on the Combination of the Synthetic TLR4 Agonist FP20 and a Synthetic QS-21 Variant. JOURNAL OF MEDICINAL CHEMISTRY, 67(24), 22254-22262 [10.1021/acs.jmedchem.4c02392]. Detail